Folic Acid Supplementation in Methotrexate Therapy

Introduction to Folic Acid Dosage

The American Academy of Dermatology recommends a minimum dose of folic acid of at least 5 mg per week for patients taking methotrexate, with daily supplementation of 1-5 mg being the most common and effective regimen 1, 2, 3

The daily regimen of 1-5 mg of folic acid, except on the day of methotrexate administration, is a common approach to reduce side effects without compromising efficacy, as suggested by the American Academy of Dermatology 2, 3
Patients with elevated risk of methotrexate toxicity may benefit from the higher end of the dosing range, which is 5 mg daily, according to the American Academy of Dermatology 3
Target dosage of 20-25 mg weekly in Western populations, individualized based on disease activity and body weight, to achieve optimal therapeutic benefits while minimizing side effects, as recommended by the American College of Rheumatology and the European League Against Rheumatism 4, 5

Regular monitoring of complete blood count, liver function, and renal function is essential for patients taking methotrexate, regardless of folic acid supplementation, as recommended by the American Academy of Dermatology 3
Initial monitoring should occur every 2-4 weeks until a stable dose is reached, then every 1-3 months, as suggested by the American Academy of Dermatology 3
Enhanced monitoring, including CBC, liver function tests, and renal function, should be performed every 2 weeks for the first month, then every 4 weeks thereafter until stable, with monitoring frequency increased with dose escalations, as recommended by the British Association of Dermatologists 6
Daily measurement of serum methotrexate levels until <0.05 μmol/L is crucial, along with monitoring of complete blood count, serum creatinine, and liver transaminases until normalization, with frequent monitoring especially important in the first 72 hours after administration [1, @5@, @6@, 6]

Folic acid supplementation does not appear to significantly reduce the efficacy of methotrexate in treating conditions such as rheumatoid arthritis or psoriasis, according to the American Academy of Dermatology 3
Folic acid supplementation of at least 5 mg daily is recommended for patients with MTHFR deficiency receiving methotrexate therapy, with higher doses (up to 10 mg daily) considered for patients with homozygous MTHFR mutations, as recommended by the American College of Rheumatology 1
The American Academy of Dermatology and the American College of Rheumatology suggest considering folic acid supplementation (1-5 mg daily except on the day of MTX) to potentially reduce the risk of MTX-induced pneumonitis, with the American College of Rheumatology recommending starting folic acid supplementation at 1 mg daily with MTX initiation, with the option to increase to higher doses as needed 2, 4

Patients with renal insufficiency, advanced age, dosing errors, drug interactions, hypoalbuminemia, obesity, diabetes, hyperlipidemia, and non-alcoholic fatty liver disease are at increased risk of methotrexate toxicity, according to the American Academy of Dermatology 3
Patients with MTHFR gene mutations are also at higher risk for toxicity, and consideration of MTHFR genotyping is recommended if prolonged high MTX levels occur, as indicated by the National Comprehensive Cancer Network 7
Baseline laboratory values, including complete blood count, liver function tests, renal function, and serum folate and vitamin B12 levels, should be assessed before initiating methotrexate in patients with MTHFR deficiency, with additional risk factors evaluated 1, 2

High-dose methotrexate (3-8 g/m²) therapy requires leucovorin rescue, as recommended by the National Comprehensive Cancer Network 7
Leucovorin rescue should be started 24 hours after the beginning of high-dose methotrexate infusion, and the dose should be adjusted based on MTX levels, as per the British Journal of Dermatology guidelines 6
The National Comprehensive Cancer Network recommends the following regimens:

Aggressive hydration and urinary alkalinization should be maintained throughout treatment to minimize the risk of toxicity, as recommended by the British Journal of Dermatology 6
In case of overdose, activated charcoal should be administered if ingestion occurred within 1 hour, followed by high-dose leucovorin (100 mg/m²) immediately, and consideration of hemodialysis for extreme cases, as per the British Journal of Dermatology guidelines 6
Glucarpidase should be considered in cases of significantly delayed elimination, particularly in patients with renal insufficiency, reducing plasma methotrexate levels by up to 86% [@2@, @4@]
Aggressive intravenous hydration (3-4 L/m²/day) and urinary alkalinization to maintain a urinary pH >7.0 should be initiated immediately in cases of toxicity or delayed elimination, along with leucovorin rescue, as recommended by the National Comprehensive Cancer Network and the American College of Medical Toxicology [@2@, @4@, 6, 7]